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ABSTRACT 
Objective: Many Fix Dose Combinations (FDCs) being introduced in India are usually irrational. The most pressing concern with irrational FDCs is 
that they expose patients to unnecessary risk of adverse drug reactions, for instance, pediatric formulations of nimesulide+paracetamol. Despite 
their wide clinical use, their gastro-intestinal toxicity is a major limitation. The aim of the present work was to evaluate the efficacy and safety of 
FDCs in non-steroidal anti-inflammatory drugs in the orthopedic department at a tertiary care teaching hospital. To study the effectiveness and 
safety parameters of fixed-dose combinations of Non-Steroidal Anti-inflammatory Drugs. 
Methods: This prospective, observational study was conducted among 150 out-patients of the orthopedic ward over a period of July 2013 to 
December 2013(Each combination with 50 patients). Three fixed-dose combinations utilized were paracetamol+diclofenac, paracetamol+ibuprofen 
and paracetamol+nimesulide. The effectiveness was analyzed by using Visual Analogue Scale (VAS) and Disease Activity Scale (DAS) and the safety 
criteria were analyzed by using the WHO probability scale and Naranjo scale. 150 orthopedic patients attending Out Patient Department were 
included. 50 participants for each of the combinations of fixed-dose combination (FDCs) of NSAIDs.  
Results: Out of 150 patients 33 patients developed adverse effects, and 17(51.51%) adverse effects due to the combination of Paracetmol+Nimuselide, 
11(33.34%) adverse effects due to the Paracetamol+Ibuprofen and 5 (15.15%) were due to the combination of Paracetamol+Diclofenac. The maximum 
effectiveness (3.55±0.208) showed in the combination of paracetamol+diclofenac compared to the other two combinations.  
Conclusion: It was concluded from this study that the effectiveness and safety profile of PCM+DICLO is better than the other two FDCs.  
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INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most 
commonly prescribed drugs in the world for their analgesic, 
antipyretic and anti-inflammatory properties. Presently, several 
varieties of fixed-dose combinations (FDCs) of NSAIDs are available 
over the counter and are being prescribed too [1]. FDCs are reviewed 
by regulating agencies (such as the Food and Drug Administration in 
the United States), the active ingredients used in the FDCs are unlikely 
to exhibit adverse drug interaction with each other [2]. However, FDCs 
may interact with other drugs that a patient is taking, so the usual 
medical and pharmaceutical precautions against drug-drug 
interactions [3]. FDCs are highly popular in the Indian pharmaceutical 
market and have been particularly flourishing in the last few years [4]. 
Many FDCs being introduced in India are usually irrational. The most 
pressing concern with irrational FDCs is that they expose patients to 
unnecessary risk of adverse drug reactions, for instance, pediatric 
formulations of nimesulide+paracetamol. Nimesulide alone is more 
antipyretic than paracetamol, more anti-inflammatory than aspirin, 
and equivalent in analgesia to any of the NSAIDS alone, so efficacy 
gains are unlikely with added paracetamol. However, the patients may 
be subject to increased hepatotoxic effects from the combination. With 
this background, the aim of the present study was to evaluate the 
efficacy and safety of FDCs (Paracetmol+Nimuselide, 
Paracetamol+Ibuprofen, Paracetamol+Diclofenac) in non-steroidal 
anti-inflammatory drugs in the orthopedic department at Karam said. 
MATERIALS AND METHODS 
Methodology  
The prospective observational study was conducted at Shree 
Krishna Hospital from July 2013 to December 2013. Ethical approval 
was obtained from the institutional ethics committee Karamsad. 
Overview of methodology 
 
Chart of an overview of the methodology 
Inclusion criteria: Both genders with the age of above 18 y 
receiving oral formulation of NSAIDs, Patients with All types of joint 
pain were included in the study. 
Exclusion criteria: Paediatric, with liver disease, CVS disease, GI 
disease, Patients who are receiving Topical drugs. 
Sample size: 150 orthopedic patients, attending the medicine Out-
Patient department were included.  
The data were analysed by using Microsoft Excel and an unpaired t-
test was applied to check the effectiveness of three fixed-dose 
combinations of NSAIDs. 
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RESULTS 
In the present study out of 150 participants one hundred patients 
were male (66.66%) and fifty (33.34%) females. In the present study 
Paracetamol+Nimesulide (PCM+NIM), Paracetamol+ Diclofenac 
(PCM+DICLO) and Paracetamol+Ibuprofen (PCM+IBU) FDCs 
were evaluated for its effectiveness and safety criteria. 
Maximum combinations were found of all three FDCs in the age 
range of 20-40 y in male participants and in females from 20-
60 y (table 1). 
 
Table 1: Utilization of FDCs with gender and age distribution 
Gender Age group No of patients Combination Total 
PCM+NIM PCM+DICLO PCM+IBU 
MALE 
(n-100) 
20-30 30 (30%) 10 11 9 30 
31-40 40 (40%) 14 13 13 40 
41-50 20 (20%) 8 6 6 20 
51-60 10 (10%) 2 3 5 10 
Female 
(n-50) 
20-30 12 (24%) 3 4 5 12 
31-40 8 (16%) 1 4 3 8 
41-50 15 (30%) 6 4 5 15 
51-60 15(30%) 5 6 3 15 
Total 50 50 50 150 
Total 77 (51.33%) patients had suffered from orthopedic conditions like trauma, tissue injury stains, and more than 50% patients were recorded 
with single morbidity (table 2). 
 
Table 2: Orthopedic patients with comorbidities 
Other comorbid conditions No of patients (N=150) % of patients 
Diabetes 37 24.66 % 
Hypertension 11 7.33 % 
Diabetes+Hypertension 17 11.34% 
COPD 7 4.6% 
PCOD 1 0.66% 
NO COMORBIDITIES 77 51.33% 
TOTAL 150 
In our study, the effectiveness scale of DAS was better in the case of PCM+DICLO and PCM+IBU compared to PCM+NIM.  
 
Patients treated with all FDCs and the disease activity score was 
calculated (fig. 1) and the maximum effectiveness 2.91±0.45 
(mean±SEM) was shown with the combination of PCM+DICLO 
compared to the other two combinations. 
  
 
Fig. 1: Effectiveness scale (DAS), the maximum effectiveness according to visual analogue scale score is 3.55±0.20 showed in the 
combination of PCM+DICLO compared to the other two combinations (fig. 2) 
 
 
Fig. 2: Effectiveness scale (VAS) 
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In our study, 33 patients developed adverse effect out of 150, and 
out of this 17 (51.51%) adverse effects were due to the combination 
of PCM+NIM, 11 (33.34%) adverse effects due to the PCM+IBU and 5 
(15.15%) adverse effects due to the combination of PCM+DICLO 
(table 3).  
Causality assessment has been done as per WHO probability scale 
and Naranjo scale, According to WHO scale 15 adverse effects were 
possible in nature and remaining 8, 7 and 3 adverse effects were 
doubtful, probable and conditional in nature, According to Naranjo 
scale 18 adverse effects were possible in nature and remaining 2 and 
11 adverse effects were doubtful and probable in nature. In this 
prospective observational study suggested that FDCs use was higher 
in male patients may be the orthopedic condition was highly 
prevalent in male patients. 
 
Table 3: Adverse effects in prescribed FDCs 
FDCs Adverse effects 
Vomiting Urticaria Constipation GI Upset Total Percentage 
PCM+NIM 5 6 4 2 17 51.51 
PCM+IBU 4 2 3 2 11 33.34 
PCM+DICL 2 0 2 1 5 15.15 
Total  11 8 9 5 33 100 
 
Table 4: Causality assessment of adverse drug reaction 
ADR WHO (%) Naranjo (%) 
Certain 0 0 
Probable 7(21%) 4(12.12%) 
Possible 15(45.45%) 18(54.54%) 
Unlikely/Doubtful 8(24.24%) 11(33.33%) 
Conditional 3(9.09%) 0 
Total 33(100%) 33(100%) 
 
Age group between 31-40 y was more prevalent for use of FDCs than 
the patients presented with single comorbidities. Comorbidities like 
diabetes, hypertension and COPD were common in this study. Out of 
these combinations, it’s showed that PCM+DICLO was more effective 
than PCM+NIM and PCM+IBU. Side effects were more prevalent with 
the use of PCM+NIM than PCM+DICLO and PCM+IBU. 
DISCUSSION 
WHO has suggested specific pain therapy protocols including simple 
analgesics to be selected at the first instance where any other 
NSAIDs do not respond well. In India currently, there is huge market 
of paracetamol and diclofenac combination [11]. This study was 
conducted with the objective of effectiveness and safety assessment 
of fixed-dose combinations of non-steroidal anti-inflammatory 
drugs. In this study, three different FDCs were used for evaluation as 
PCM+DICLO, PCM+IBU, and PCM+NIM. Here selected FDCs are most 
frequently used in therapy for orthopedic conditions.  
In present study out of 150 patients Comorbidity observed as 
37(24.66%) patients with diabetes, 17(11.34%) patients with 
diabetes and hypertension, 11(7.33%) patients with hypertension 
only, 7(4.6%) patients having COPD and 1(0.66%) patients with 
PCOD. The previous study showed that maximum patients observed 
with comorbidity of Diabetes (29%) while remaining were COPD, 
renal disease, hypertension [6]. Another study observed maximum 
patients with comorbidity of diabetes (32%) along with blood 
pressure, COPD, renal disease, heartburn, headache, urinary disease 
[7], which supported our study results. 
Present work showed the effectiveness of DAS in a better way for 
PCM+DICLO and PCM+IBU compared to PCM+NIM. In the study 
conducted by Merryet AF et al., observed DAS interpreted the 
maximum effect of the drug (3.55±0.37) from a combination of 
Paracetamol+Ketoralac than of Paracetamol+Oxaprozin and 
Paracetamol+Ibuprofen. In this study, Paracetamol+Ketoralac is 
more effective than the other two types of combination [8]. In other 
studies by Spofford CM et al. DAS interpreted the maximum effect of 
drug (2.79±0.27) from a combination of Paracetamol+Diclofenac 
than the other two combinations of Paracetamol+Ibuprofen and 
Paracetamol+Tolmetin, which was supporting our study results. In 
one study the Paracetamol+Diclofenac is more effective than other 
two types of combination also supporting our study results [9]. 
Anderson JK et al. showed DAS which interpreted the maximum 
effect of the drug (2.97±0.17) from a combination of 
Paracetamol+Ketoralac than their two combinations of 
Paracetamol+Oxaprozin and Paracetamol+Ibuprofen. In this study, 
Paracetamol+Ketoralac is more effective than the other two types of 
combination [10]. Williams DL et al. interpreted the maximum effect 
of the drug (2.67±0.11) from a combination of Paracetamol+ 
Diclofenac than their two combinations of Paracetamol+Ibuprofen 
and Paracetamol+Tolmetin for DAS. In this study, 
Paracetamol+Diclofenac is more effective than the other two types 
of combination [11]. The study conducted by a group of scientists 
showed significant pain control in the diclofenac group, whereas the 
duration of action is significantly increased in hydroxychloroquine 
[13]. Here It was seen that the incidence of gastric ulcers more 
common in the diclofenac group when compared to the 
hydroxychloroquine group. In another study, it was observed that 
Diclofenac sodium tablets, diclofenac sodium injection, oral 
paracetamol, and oral ibuprofen were prescribed as 45.1%, 27.5%, 
15.9%, and 11.5%, respectively [14]. 
Two major scales (WHO, Naranjo scale) were used to assess the causality 
for adverse effects (AE). The major AE observed were vomiting, 
urticaria, constipation, and GI upset. Possible scale observed very high in 
the case of the WHO and Naranjo scale in our study. Out of 150 patients, 
33 patients develop adverse effects, and 51.51% adverse effects due to 
the combination of PCM+NIM, 33.34% adverse effects due to the 
PCM+IBU and 15.15% adverse effects due to the combination of 
PCM+DICLO. One scientific study showed that PCM+NIM was the culprit 
in causing ADRs in 60% and PCM+DICLO was in 40% of the participants. 
GI-related adverse reaction observed in 28 participants. It was found 
that eighty percent of the adverse reaction was possible in nature [12], 
which supported our study results.  
CONCLUSION 
The present study concluded that the effectiveness profile of 
PCM+DICLO was better than the other two FDCs (PCM+NIM and 
PCM+IBU) in the major orthopedic condition by observing VAS and 
DAS. It was also concluded that the Safety profile of PCM+DICLO was 
better than the other two FDCs prescribed in the major orthopedic 
conditions by observing Naranjo scale and WHO probability scale. 
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